[4] Baldwin, W
Support & Care Breakdown Live Chat AI Chat on the main site is AI-only, but unlike most AI bots in this category, it was responsive and useful for quick questions
Cajon Blvd, San Bernardino, CA 92407, USA Review counts shown on landing page: 10,978 and 10,257 (inconsistent, both brand-reported) Regulatory category: marketed as a dietary supplement
This approach treats obesity as the chronic condition it is rather than something to cure and move on from
The glucagon component may contribute an additional vasodilatory effect that amplifies the blood pressure benefit relative to GLP-1-only compounds
The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough
